Ascentage Pharma's Bcl-2 Selective Inhibitor Lisaftoclax Approved By China's NMPA For Treatment Of Adult Patients With CLL/SLL

Author: Benzinga Newsdesk | July 10, 2025 08:32am

Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855))), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton's tyrosine kinase (BTK) inhibitors, which makes lisaftoclax the first Bcl-2 inhibitor receiving conditional approval and marketing authorization for the treatment of patients with CLL/SLL in China, and the second Bcl-2 inhibitor approved globally.

Posted In: AAPG